Akkermansia muciniphila helps in the recovery of lipopolysaccharide-fed mice with mild intestinal dysfunction

Area of Science:

• Microbiology
• Immunology
• Gastroenterology

Background:

• Lipopolysaccharide (LPS) from Gram-negative bacteria can induce mild intestinal dysfunction and inflammation.
• Akkermansia muciniphila is a probiotic known for its role in mucin degradation and short-chain fatty acid production, suggesting potential gut health benefits.

Purpose of the Study:

• To investigate the therapeutic effects of Akkermansia muciniphila on lipopolysaccharide (LPS)-induced mild intestinal dysfunction in a mouse model.
• To analyze the impact of Akkermansia muciniphila supplementation on gut microbiota composition and immune gene expression.

Main Methods:

• Thirty-eight C57BL/6 mice were divided into control and LPS-treated groups.
• LPS-treated mice received daily LPS for 4 weeks, followed by supplementation with Akkermansia muciniphila at two different doses for another 4 weeks.
• Gut microbiota was analyzed using metagenomic sequencing, and gene expression was assessed via transcriptomics.

Main Results:

• LPS treatment significantly altered gut microbiota, decreasing diversity and increasing pathogenic bacteria.
• Akkermansia muciniphila supplementation partially restored gut microbiota balance, increasing beneficial genera like Muribaculum.
• Transcriptomic analysis revealed that LPS induced inflammatory responses (e.g., TNF, NF-kappa B signaling), which were mitigated by Akkermansia muciniphila.

Conclusions:

• Akkermansia muciniphila effectively mitigates LPS-induced gut dysfunction in mice.
• The probiotic restores gut microbiota balance and modulates key immune and inflammatory pathways.
• Akkermansia muciniphila shows promise as a therapeutic agent for improving gut health.